The Use of Purified Clotting Factor Concentrates in Hemophilia
Influence of Viral Safety, Cost, and Supply on Therapy
- Glenn F. Pierce, MD, PhD;
- Jeanne M. Lusher, MD;
- Alan P. Brownstein, MPH, MSW;
- Jonathan C. Goldsmith, MD;
- Craig M. Kessler, MD
- From the Departments of Pathology and Medicine, Washington University Medical Center, St Louis, Mo (Dr Pierce); the Department of Pediatrics, Wayne State University School of Medicine, Detroit, Mich (Dr Lusher); the National Hemophilia Foundation, New York, NY (Mr Brownstein); the Department of Medicine, University of Nebraska Medical Center, Omaha (Dr Goldsmith); and the Department of Medicine, George Washington University School of Medicine, Washington, DC (Dr Kessler). Dr Pierce is now with the Department of Experimental Pathology, Amgen, Thousand Oaks, Calif.
Abstract
Treatment of hemophilia, although greatly improved in recent years, continues to be problematic owing to infectious complications of blood product replacement therapy. This report examines the therapeutic options presently available for the treatment of hemophilia, focusing on the potential for repeated viral exposure to influence the progression of infectious disease, decreased risks of viral transmission with blood products produced using newer viral inactivation procedures, higher economic costs of newer blood products, and the current inadequate supply of blood products in the United States.
(JAMA. 1989;261:3434-3438)
Footnotes
-
Reprint requests to the Division of Hematology-Oncology, George Washington University Medical Center, 2150 Pennsylvania Ave NW, Washington, DC 20037 (Dr Kessler).
